Discovery that theonellasterol a marine sponge sterol is a highly selective FXR antagonist that protects against liver injury in cholestasis

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Renga, Barbara ^a   Mencarelli, Andrea ^a   D'Amore, Claudio ^a   Cipriani, Sabrina ^a   D'Auria, Maria Valeria ^b   Sepe, Valentina ^b   Chini, Maria Giovanna ^c   Monti, Maria Chiara ^c   Bifulco, Giuseppe ^c   Zampella, Angela ^b   Fiorucci, Stefano ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF SALERNO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BILE ACID; ESTROGEN RECEPTOR; GLUCOCORTICOID RECEPTOR; LIVER PROTECTIVE AGENT; MULTIDRUG RESISTANCE PROTEIN 4; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN LXR; PROTEIN PXR; RECEPTOR PROTEIN; THEONELLASTEROL; THYROID RECEPTOR; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR; 7 HYDROXYTHEONELLASTEROL; 7-HYDROXYTHEONELLASTEROL; CELL RECEPTOR; FARNESOID X RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR; HORMONE ANTAGONIST; STEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOASSAY; BSEP GENE; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG EFFECT; DRUG ISOLATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; EXTRAHEPATIC BILE DUCT OBSTRUCTION; HISTOPATHOLOGY; IN VIVO STUDY; LIVER CELL; LIVER HISTOLOGY; LIVER INJURY; LIVER NECROSIS; LIVER PROTECTION; MICROARRAY ANALYSIS; MOLECULAR DOCKING; MOUSE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4 GENE; NONHUMAN; OSTALPHA GENE; PROTEIN EXPRESSION; REGULATOR GENE; SHP GENE; TRANSACTIVATION; ANIMAL; AQUATIC SPECIES; CELL PROTECTION; CHEMISTRY; DISEASE MODEL; DRUG ANTAGONISM; DRUG DEVELOPMENT; DRUG SCREENING; ENZYME SPECIFICITY; FEASIBILITY STUDY; HUMAN; INJURY; INTRAHEPATIC CHOLESTASIS; ISOLATION AND PURIFICATION; LIVER; PATHOLOGY; SPONGE (PORIFERA);

MUS; RODENTIA; THEONELLA SWINHOEI;

ANIMALS; AQUATIC ORGANISMS; CHOLESTASIS, INTRAHEPATIC; CYTOPROTECTION; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; FEASIBILITY STUDIES; HEP G2 CELLS; HORMONE ANTAGONISTS; HUMANS; LIVER; MICE; PORIFERA; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STEROLS; SUBSTRATE SPECIFICITY;

EID: 84856084764     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030443     Document Type: Article

References (36)

1. Fiorucci S, Baldelli F, (2009) Farnesoid X receptor agonists in biliary tract disease. Curr Opin Gastroenterol 25: 252-259.
2. Jonker JW, Liddle C, Downes M, (2011) FXR and PXR: potential therapeutic targets in cholestasis. J Steroid Biochem Mol Biol doi:10.1016/j.jsbmb.2011.06.012.
3. Stedman C, Liddle C, Coulter S, Sonoda J, Alvarez JG, et al. (2006) Benefit of farnesoid X receptor inhibition in obstructive cholestasis. Proc Natl Acad Sci USA 103 (30): 11323-11328.
4. Mennone A, Soroka CJ, Cai SY, Harry K, Adachi M, et al. (2006) Mrp4-/- mice have an impaired cytoprotective response in obstructive cholestasis. Hepatology 43: 1013-1021.
5. Renga B, Migliorati M, Mencarelli A, Cipriani S, D'Amore C, et al. (2011) Farnesoid X receptor suppresses constitutive androstane receptor activity at the multidrug resistance protein-4 promoter. Biochim Biophys Acta 3: 157-165.
6. Stedman CA, Liddle C, Coulter SA, Sonoda J, Alvarez JG, et al. (2005) Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury. Proc Natl Acad Sci USA 102: 2063-2068.
7. Sepe V, Ummarino R, D'Auria MV, Chini MG, Bifulco G, et al. (2011) Conicasterol E, a small heterodimer partner sparing farnesoid-X-receptor modulator endowed with a pregnane-X-receptor agonistic activity, from the marine sponge Theonella swinhoei. J Med Chem Nov 29. [Epub ahead of print].
8. Fiorucci S, Cipriani S, Mencarelli A, Baldelli F, Bifulco G, Zampella A, (2011) Farnesoid X Receptor Agonist for the Treatment of Liver and Metabolic Disorders: Focus on 6-ethyl-CDCA. Mini Rev Med Chem 11: 753-762.
9. Li JWH, Vederas JC, (2009) Drug discovery and natural products: end of an era or an endless frontier? Science 325: 161-165.
10. Carlson EE, (2010) Natural products as chemical probes. ACS Chem Biol 5: 639-653.
11. Nishimura S, Arita Y, Honda M, Iwamoto K, Matsuyama A, et al. (2010) Marine antifungal theonellamides target 3beta-hydroxysterol to activate Rho1 signaling. Nat Chem Biol 6: 519-526.
12. Kobayashi M, Tanaka J, Katori T, Kitagawa I, (1989) Structure of swinholide A, a potent cytotoxic macrolide from the Okinawan marine sponge Theonella swinhoei. Tetrahedron Lett 30: 2963-2966.
13. De Marino S, Ummarino R, D'Auria MV, Chini MG, Bifulco G, et al. (2011) Theonellasterols and conicasterols from Theonella swinhoei. Novel marine natural ligands for human nuclear receptors. J Med Chem 54: 3065-3075.
14. Kho E, Imagawa DK, Rohmer M, Kashman Y, Djerassi C, (1981) Sterols in marine invertebrates. 22. Isolation and structure elucidation of conicasterol and theonellasterol, two new 4-methylene sterols from the Red Sea sponges Theonella conica and Theonella swinhoei. J Org Chem 46: 1836-1839.
15. Soisson SM, Parthasarathy G, Adams AD, Sahoo S, Sitlani A, et al. (2008) Identification of a potent synthetic FXR agonist with an unexpected mode of binding and activation. Proc Natl Acad Sci U S A 105: 5337-5342.
16. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, et al. (2009) AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 30: 2785-2791.
17. Downes M, Verdecia MA, Roecker AJ, Hughes R, Hogenesch JB, et al. (2003) A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol Cell 11: 1079-1092.
18. Akwabi-Ameyaw A, Bass JY, Caldwell RD, Caravella JA, Chen L, et al. (2008) Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064. Bioorg Med Chem Lett 18: 4339-4343.
19. Akwabi-Ameyaw A, Caravella JA, Chen L, Creech KL, Deaton DN, et al. (2011) Conformationally constrained farnesoid X receptor (FXR) agonists: alternative replacements of the stilbene. Bioorg Med Chem Lett 21: 6154-6160.
20. Mi LZ, Devarakonda S, Harp JM, Han Q, Pellicciari R, et al. (2003) Structural basis for bile acid binding and activation of the nuclear receptor FXR. Mol Cell 11: 1093-1100.
21. Urizar NL, Liverman AB, Dodds DT, Silva FV, Ordentlich P, et al. (2002) A natural product that lowers cholesterol as an antagonist ligand for FXR. Science 31: 1703-1706.
22. Meyer U, Costantino G, Macchiarulo A, Pellicciari R, (2005) Is antagonism of E/Z-guggulsterone at the farnesoid X receptor mediated by a noncanonical binding site? A molecular modeling study. J Med Chem 48: 6948-6955.
23. Fiorucci S, Mencarelli A, Palladino G, Cipriani S, (2009) Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. Trends Pharmacol Sci 30: 570-80.
24. Bridgham JT, Eick GN, Larroux C, Deshpande K, Harms MJ, et al. (2010) Protein evolution by molecular tinkering: diversification of the nuclear receptor superfamily from a ligand-dependent ancestor. PLoS Biol 8 (10): pii e1000497.
25. Wu J, Xia C, Meier J, Li S, Hu X, Lala DS, (2002) The hypolipidemic natural product guggulsterone acts as an antagonist of the bile acid receptor. Mol Endocrinol 16: 1590-1597.
26. Owsley E, Chiang JY, (2003) Guggulsterone antagonizes farnesoid X receptor induction of bile salt export pump but activates pregnane X receptor to inhibit cholesterol 7alpha-hydroxylase gene. Biochem Biophys Res Commun 304: 191-195.
27. Brobst DE, Ding X, Creech KL, Goodwin B, Kelley B, Staudinger JL, (2004) Guggulsterone activates multiple nuclear receptors and induces CYP3A gene expression through the pregnane X receptor. J Pharmacol Exp Ther 310 (2): 528-35.
28. Burris TP, Montrose C, Houck KA, Osborne HE, Bocchinfuso WP, et al. (2005) The hypolipidemic natural product guggulsterone is a promiscuous steroid receptor ligand. Mol Pharmacol 67: 948-954.
29. Teng S, Piquette-Miller M, (2007) Hepatoprotective role of PXR activation and MRP3 in cholic acid-induced cholestasis. Br J Pharmacol 151: 367-76.
30. Beilke LD, Aleksunes LM, Holland RD, Besselsen DG, Beger RD, et al. (2009) Constitutive androstane receptor-mediated changes in bile acid composition contributes to hepatoprotection from lithocholic acid-induced liver injury in mice. Drug Metab Dispos 37: 1035-45.
31. Fiorucci S, Antonelli E, Rizzo G, Renga B, Mencarelli A, et al. (2004) The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 127: 1497-512.
32. Liu Y, Binz J, Numerick MJ, Dennis S, Luo B, et al. (2003) Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J Clin Invest 112: 1678-1687.
33. Sanner MF, (1999) Python: A Programming Language for Software Integration and Development. J Mol Graphics Modell 17: 57-61.
34. Lian Y, Suya L, Meng W, Yong S, Min D, (2007) High-performance liquid chromatography-tandem mass spectrometry for the analysis of bile acid profiles in serum of women with intrahepatic cholestasis of pregnancy. J Chromatogr B 860: 10-17.
35. Huang J, Bathena SPR, Csanaky IL, Alnouti Y, (2011) Simultaneous characterization of bile acids and their sulfate metabolites in mouse liver, plasma, bile and urine using LC-MS-MS. J Pharm Biomed Anal 55: 1111-1119.
36. Bobeldijk I, Hekman M, de Vries-van derWeij J, Couliera L, Ramakera R, et al. (2008) Quantitative profiling of bile acids in biofluids and tissues based on accurate mass high resolution LC-FT-MS: Compound class targeting in a metabolomics workflow. J Chromatogr B 871: 306-313.